Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 3;78(4):1034-1040.
doi: 10.1093/jac/dkad042.

Early initiation of three-drug combinations for the treatment of carbapenem-resistant A. baumannii among COVID-19 patients

Emily L Heil  1 , Kimberly C Claeys  1 , Ellen G Kline  2 , Tara M Rogers  2 , Kevin M Squires  2 , Alina Iovleva  2 , Yohei Doi  2 , Mary Banoub  3 , Mandee M Noval  3 , Paul M Luethy  4 , Ryan K Shields  2
Affiliations

Early initiation of three-drug combinations for the treatment of carbapenem-resistant A. baumannii among COVID-19 patients

Emily L Heil et al. J Antimicrob Chemother. .

Abstract

Objectives: We evaluated the clinical characteristics and outcomes of patients with COVID-19 who received three-drug combination regimens for treatment of carbapenem-resistant Acinetobacter baumannii (CRAB) infections during a single-centre outbreak. Our objective was to describe the clinical outcomes and molecular characteristics and in vitro synergy of antibiotics against CRAB isolates.

Materials and methods: Patients with severe COVID-19 admitted between April and July 2020 with CRAB infections were retrospectively evaluated. Clinical success was defined as resolution of signs/symptoms of infection without need for additional antibiotics. Representative isolates underwent whole-genome sequencing (WGS) and in vitro synergy of two- or three-drug combinations was assessed by checkerboard and time-kill assays, respectively.

Results: Eighteen patients with CRAB pneumonia or bacteraemia were included. Treatment regimens included high-dose ampicillin-sulbactam, meropenem, plus polymyxin B (SUL/MEM/PMB; 72%), SUL/PMB plus minocycline (MIN; 17%) or other combinations (12%). Clinical resolution was achieved in 50% of patients and 30-day mortality was 22% (4/18). Seven patients had recurrent infections, during which further antimicrobial resistance to SUL or PMB was not evident. PMB/SUL was the most active two-drug combination by checkerboard. Paired isolates collected before and after treatment with SUL/MEM/PMB did not demonstrate new gene mutations or differences in the activity of two- or three-drug combinations.

Conclusions: Use of three-drug regimens for severe CRAB infections among COVID-19 resulted in high rates of clinical response and low mortality relative to previous studies. The emergence of further antibiotic resistance was not detected phenotypically or through WGS analysis. Additional studies are needed to elucidate preferred antibiotic combinations linked to the molecular characteristics of infecting strains.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Time-kill assays performed for paired initial and recurrent isolates from one patient (MICU-1) collected before and after 21 days of ampicillin-sulbactam, meropenem, and polymyxin b treatment did not demonstrate the emergence of new resistance gene mutations or differences in the killing activity of 2- or 3-drug combinations. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
See this image and copyright information in PMC

References

    1. Wong D, Nielsen TB, Bonomo Ret al. . Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges. Clin Microbiol Reviews 2017; 30: 409–47. 10.1128/CMR.00058-16 - DOI - PMC - PubMed
    1. Esterly JS, Griffith M, Qi Cet al. . Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections. Antimicrob Agents Chemother 2011; 55: 4844–9. 10.1128/AAC.01728-10 - DOI - PMC - PubMed
    1. Isler B, Doi Y, Bonomo RAet al. . New treatment options against carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother 2019; 63: e01110–18. 10.1128/AAC.01110-18 - DOI - PMC - PubMed
    1. Bassetti M, Echols R, Matsunaga Yet al. . Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 2021; 21: 226–40. 10.1016/S1473-3099(20)30796-9 - DOI - PubMed
    1. Qureshi ZA, Hittle LE, O’Hara JAet al. . Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis 2015; 60: 1295–303. 10.1093/cid/civ048 - DOI - PMC - PubMed

Publication types